Orphan drugs assessment in the centralised procedure

Area of Science:

• Pharmacovigilance and Regulatory Science
• Rare Disease Therapeutics
• Drug Approval Processes

Background:

• Orphan drugs are crucial for treating rare diseases, but patient access is often limited.
• The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) plays a key role in drug approval.
• Current regulatory pathways may present barriers to timely access for novel orphan medicines.

Purpose of the Study:

• To propose recommendations for facilitating patient access to new orphan drugs.
• To suggest improvements in the European Medicines Agency's (EMA) drug evaluation and approval processes.
• To advocate for a more patient-centric approach in regulatory decision-making for rare disease treatments.

Main Methods:

• Analysis of regulatory processes based on expert experience within the CHMP.
• Formulation of suggestions for regulatory bodies and EMA Committees.
• Review of existing guidelines and their interpretation in the context of rare diseases.

Main Results:

• Advocacy for more frequent use of conditional approval and approval under exceptional circumstances.
• Emphasis on incorporating the opinions of rare disease societies and patient associations.
• Recommendation for flexible interpretation of guideline requirements and prioritizing quality of life improvements.
• Suggestion to weigh unmet medical needs and patient-reported outcomes over rigid statistical significance.

Conclusions:

• Regulatory frameworks should be adapted to better accommodate the unique challenges of orphan drug development.
• A more flexible and patient-centered approach by regulatory bodies can significantly improve access to life-saving rare disease therapies.
• Amendments to current legislation may be necessary to optimize the orphan drug approval pathway.